Form 4: BIO-TECHNE Executive Reports Stock Transaction
Insider Transaction (Form 4)
Shane Bohnen, SVP - General Counsel of BIO-TECHNE Corp, reported multiple transactions in common stock on July 23, 2026.
Summary
- Option exercise/conversion: acquired 448 Common Stock at $47.60 ($21,325) on July 23, 2026; holds 7,697 after (Direct).
- Tax/exercise-price withholding: disposed of 344 Common Stock at $71.77 ($24,689) on July 23, 2026; holds 7,353 after (Direct).
- Option exercise/conversion: disposed of 448 Stock Option (Right to Buy) on July 23, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Shane Bohnen — Officer (SVP - General Counsel)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-23 | Option exercise/conversion | Common Stock | 448 | $48 | $21.3K | 7,697 |
| 2026-07-23 | Tax/exercise-price withholding | Common Stock | 344 | $72 | $24.7K | 7,353 |
| 2026-07-23 | Option exercise/conversion | Stock Option (Right to Buy) | 448 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-23 | Option exercise/conversion (448 shares) |
| 2026-07-23 | Tax/exercise-price withholding (344 shares) |
| 2026-07-23 | Option exercise/conversion (448 shares) |
Keywords
insider transaction, Form 4, TECH, BIO-TECHNE Corp, neutral, Shane Bohnen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.